Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) has received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Analysts have set a 1-year consensus target price of $26.75 for the company, according to Zacks. Zacks has also given Verona Pharma PLC American Depositary Share an industry rank of 167 out of 265 based on the ratings given to related companies.

Several brokerages have issued reports on VRNA. Zacks Investment Research upgraded Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, July 25th. Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Verona Pharma PLC American Depositary Share in a report on Friday, September 8th.

COPYRIGHT VIOLATION WARNING: “Zacks: Verona Pharma PLC American Depositary Share (VRNA) Given Consensus Recommendation of “Strong Buy” by Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/04/zacks-verona-pharma-plc-american-depositary-share-vrna-given-consensus-recommendation-of-strong-buy-by-analysts.html.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ VRNA) opened at $13.55 on Friday.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.09). research analysts expect that Verona Pharma PLC American Depositary Share will post -2.23 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of VRNA. FIL Ltd bought a new position in shares of Verona Pharma PLC American Depositary Share in the second quarter valued at approximately $873,000. Tekla Capital Management LLC bought a new stake in Verona Pharma PLC American Depositary Share during the second quarter worth $3,211,000. Finally, Vivo Capital LLC bought a new stake in Verona Pharma PLC American Depositary Share during the second quarter worth $8,208,000. Institutional investors own 30.16% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.